According to a recent study in Human Reproduction, women who produce a low number of oocytes during in vitro fertilization (IVF) seem to have an increased risk of miscarriage.
According to a recent study in Human Reproduction, women who produce a low number of oocytes during in vitro fertilization (IVF) seem to have an increased risk of miscarriage.
Researchers at the University of Birmingham looked at data from the Human Fertilization and Embryology Authority, collected from 1991 to June 2008, covering 402,185 stimulated fresh IVF cycles and 124,351 resulting pregnancies.
A strong association between the number of oocytes retrieved per IVF cycle and the clinical miscarriage rate was found. Logistic regression identified 3 cut-off points where the probability of clinical miscarriage fell: 4, 10, and 15 oocytes. Women who produced <4 oocytes had a miscarriage rate of 20%; the miscarriage rate was 15.5% for women who produced between 4 and 9 oocytes; and women with 10 to 14 oocytes had a miscarriage rate of 13.8%. No increase in miscarriage risk was found in women who produced very high numbers of oocytes (>20 oocytes). The lowest risk of miscarriage was found in women younger than age 38, with primary infertility without a female cause, and who produced more than 3 oocytes.
The investigators said that the data were limited by a lack of information on the total gonadotropin consumption and confounders such as body mass index. They also concluded that the high rate of miscarriage is more than likely associated with a decline in the quality of the oocytes.
To get weekly advice for today's Ob/Gyn, subscribe to the Contemporary Ob/Gyn Special Delivery.
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
How genetic variables impact oral contraceptive use and VTE risk
March 27th 2024A comprehensive study delved into the interplay of polygenic and hereditary factors in venous thromboembolism risk among oral contraceptive users, shedding light on potential genetic markers for refined risk assessment and counseling.
Read More
FDA grants FTD to nipocalimab for treating FNAIT
March 26th 2024The FDA's Fast Track Designation for nipocalimab marks a significant step in addressing fetal neonatal alloimmune thrombocytopenia risk in pregnant patients, potentially revolutionizing treatment for this severe condition with unmet medical needs.
Read More
Study links low neighborhood food access to adverse birth outcomes
March 26th 2024A recent study highlighted the link between residence in low-income areas with limited food access during pregnancy and increased risks of lower birth weight and small for gestational age infants, urging further investigation into potential interventions for improved birth outcomes.
Read More